Sign In
Buy AIM
$0.732
-0.0947 (-11.46%)
At Close: Jun 03, 2026
AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
09:05am, Friday, 22'nd Sep 2023
OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present a
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
09:05am, Tuesday, 05'th Sep 2023
OCALA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM, will p
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
09:05am, Wednesday, 09'th Aug 2023
OCALA, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to disc
AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
08:45am, Wednesday, 14'th Jun 2023
OCALA, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeut
AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast
08:50am, Tuesday, 09'th May 2023
OCALA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeuti
OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeut
AIM ImmunoTech shares rise on news of pancreatic cancer research partnership with AstraZeneca and Erasmus Medical Center
10:26am, Tuesday, 17'th Jan 2023
AIM ImmunoTech Inc (NYSE:AIM) (AIM) announced that it has entered into an external sponsored collaborative clinical research agreement with AstraZeneca and Erasmus Medical Center in the Netherlands t
5 Penny Stocks To Watch After Big News This Week
09:24am, Tuesday, 17'th Jan 2023
Penny stocks to watch with news that are turning heads in the stock market this week. The post 5 Penny Stocks To Watch After Big News This Week appeared first on Penny Stocks to Buy, Picks, News and I
AIM ImmunoTech broadens patent portfolio with new Netherlands utility patent
09:25am, Monday, 09'th Jan 2023
AIM ImmunoTech Inc (NYSE:AIM) has announced that the Netherlands Patent Office has granted the company a utility patent covering rugged dsRNA, a double-stranded RNA product related to its lead candida
AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event'
08:45am, Thursday, 05'th Jan 2023
Live video webcast on Wednesday, January 18th at 11:00 AM ET Live video webcast on Wednesday, January 18th at 11:00 AM ET
AIM ImmunoTech promotes Christopher McAleer to the role of scientific officer
09:49am, Monday, 12'th Dec 2022
AIM ImmunoTech Inc (NYSE:AIM) has announced the promotion of Christopher McAleer from the company's deputy scientific officer to the position of scientific officer. The immuno-pharma firm said McAlee
AIM ImmunoTech reports positive safety, tolerability, and biological activity data from Phase 1 Ampligen study
09:06am, Thursday, 08'th Dec 2022
AIM ImmunoTech Inc (NYSE:AIM) has reported positive safety, tolerability, and biological activity data from a Phase 1 study involving the intranasal administration of its lead product Ampligen (rintat
AIM ImmunoTech says cash position expected to fund operations through end of 2023
09:32am, Tuesday, 15'th Nov 2022
AIM ImmunoTech Inc (NYSE:AIM) said it ended the third quarter of 2022 with cash and cash equivalents of $36.7 million, down from $48.3 million at the end of December 2021, but expected to fund operat
AIM ImmunoTech shows positive results using Ampligen in treating triple negative breast cancer
09:13am, Monday, 14'th Nov 2022
AIM ImmunoTech Inc (NYSE:AIM) has revealed positive data evaluating Ampligen (rintatolimod) as a component of a regimen for the treatment of early-stage triple negative breast cancer. Led by by Roswe
Aimia: Trading Close To Net Cash + Marketable Securities With M&A Optionality
07:35pm, Sunday, 13'th Nov 2022
Aimia is trading approximately around its net cash plus marketable securities value. Applying punitive discounts to its private investments, Aimia's NAVPS is roughly 30% above where the stock is tradi
